United Kingdom Hyperglycemia Treatment Market Insight
United Kingdom Hyperglycemia Treatment Market is growing at an 12.19% CAGR, by rising diabetes prevalence, advanced glucose monitoring, innovative insulin therapies
United Kingdom Hyperglycemia Treatment Market Insights Forecasts to 2035
- The United Kingdom Hyperglycemia Treatment Market Size Was Estimated at USD 632.7 Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 12.19% from 2025 to 2035
- The United Kingdom Hyperglycemia Treatment Market Size is Expected to Reach USD 1998.4 Million by 2035
Notable Insights for United Kingdom Hyperglycemia Treatment Market
- By drug class, insulin therapies dominated, accounting for approximately 45% share in 2024, driven by increasing insulin-dependent diabetes cases and long-term disease management needs.
- By therapy type, oral antidiabetic drugs held approximately 55% market share, supported by widespread use of metformin, SGLT2 inhibitors, and DPP-4 inhibitors in Type 2 diabetes management.
- Approximately 8% of the UK population lives with diabetes or persistent hyperglycemia-related conditions, increasing demand for effective glucose-lowering therapies.
- Around 75% of diagnosed diabetic patients receive long-term pharmacological treatment, while adoption of combination therapies and digital glucose monitoring solutions continues to increase.
Download the eBook (ToC)
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the United Kingdom Hyperglycemia Treatment Market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in United Kingdom Hyperglycemia Treatment Market
- Novo Nordisk
- Eli Lilly and Company
- Sanofi
- AstraZeneca
- Merck & Co.
- Boehringer Ingelheim
- Abbott Laboratories
- Medtronic
- Roche Diabetes Care
- Dexcom
- Others
Recent Developments:
- In March 2026 – Eli Lilly reported positive Phase 3 retatrutide trial results, showing significant blood sugar and weight reductions through triple-hormone GLP-1, GIP, and glucagon receptor targeting for diabetes treatment.
- In February 2026 – NICE confirmed NHS adoption of generic dapagliflozin, with projected savings exceeding £560 million during 2025/26 and 2026/27, supporting reinvestment into specialized diabetes care and hyperglycemia management services.
Market Segmentation:
United Kingdom Hyperglycemia Treatment Market, By Drug Class
- Insulin Therapies
- Biguanides (Metformin)
- SGLT2 Inhibitors
- GLP-1 Receptor Agonists
- DPP-4 Inhibitors
- Sulfonylureas
- Others
United Kingdom Hyperglycemia Treatment Market, By Route of Administration
- Oral
- Injectable
United Kingdom Hyperglycemia Treatment Market, By End User
- Hospitals & Clinics
- Home Care Settings
- Specialty Diabetes Centers
United Kingdom Hyperglycemia Treatment Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Channels
Expert Views:
The UK Hyperglycemia Treatment Market is expected to grow owing to factors such as growing rates of diabetes, age trends within the country, and increasing number of metabolic conditions arising from obesity. It should be noted that GLP-1 Receptor Agonists, SGLT2 Inhibitors, and Continuous Glucose Monitoring Systems are among those factors that have been identified to continue driving market growth, backed up by NHS diabetes prevention and management programs.